MILAN & DARMSTADT, Germany--(BUSINESS WIRE)--Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced results from two surveys which further support the revolutionary role Erbitux® (cetuximab) continues to have in the treatment of head and neck cancer. Data from two key surveys, presented at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, show that Erbitux is a standard of care and preferred partner in both LA SCCHN1 and 1st line R/M SCCHN.2
